Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics

Published: Feb. 21, 2025

Hepatitis B virus (HBV) infection is a major risk factor of cirrhosis and hepatocellular carcinoma (HCC) worldwide. Pathogenesis HBV-induced HCC involves viral factors virus-triggered local inflammatory immune responses, the latter leading to progressive fibrosis, carcinogenesis. Antiviral therapeutics suppress HBV replication reduce risks HCC. We discuss current knowledge on pathogenesis HCC, focusing mechanisms emerging antiviral therapeutics.

Language: Английский

---

Mechanisms Underlying Delayed loss of HBeAg and HBV DNA Following HBsAg Seroclearance in PEG-IFNα Treated Patients of chronic hepatitis B

Emerging Microbes & Infections, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Background & Aims: A notable proportion of CHB patients undergoing PEG-IFNα based therapy experience lagged serum HBeAg and/or HBV DNA disappearance in achieving HBsAg loss. In this study, we explored the molecular mechanisms behind clinical phenomenon, offering novel insights into sustainability chronic infection.

Language: Английский

---

Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung

Deutsches Ärzteblatt, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

---

Toward functional cure of hepatitis B: Is combination therapy the key?

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

---

Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Language: Английский

---